Biosimilar Candidates
Oncology, Autoimmune Diseases
Key Facts
About China Resources Pharmaceutical Group
As a subsidiary of the state-owned China Resources Group, China Resources Pharmaceutical Group is a major player in China's healthcare sector, focusing on the research, development, production, and distribution of pharmaceutical products. The company has established a comprehensive business model encompassing pharmaceutical manufacturing, distribution, and retail pharmacy chains. Its strategic direction leverages its extensive distribution network and manufacturing capabilities to capitalize on China's growing healthcare market, while also pursuing innovation through its R&D pipeline.
View full company profileAbout Gulf Pharmaceutical Industries
Gulf Pharmaceutical Industries, known as Julphar, is a publicly listed company on the Abu Dhabi Securities Exchange (ADX) with a mission to provide high-quality, affordable medicines to the MENA region and beyond. The company has established itself through a diversified portfolio spanning diabetes, cardiovascular, gastroenterology, and anti-infective therapeutic areas. Its strategic direction includes expanding its biosimilars pipeline and leveraging its extensive manufacturing and distribution network for regional growth.
View full company profileTherapeutic Areas
Other Oncology, Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilars Pipeline | Laurus Labs | Development |
| Novel Monoclonal Antibodies | Changchun High-Tech Industry | Pre-clinical |
| Biosimilar (Rituximab) | Ipca Laboratories | Development |
| Biosimilars (e.g., trastuzumab, rituximab) | Aspen Pharmacare | Approved |
| Biosimilar Pipeline (Confidential) | Gland Pharma | Development |